A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?

In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。